MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing...
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term...
MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland, September 9, 2024 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.7 | -3.15574531279 | 53.87 | 58.26 | 50.4 | 262490 | 53.28743755 | CS |
4 | -0.13 | -0.248565965583 | 52.3 | 58.26 | 50.4 | 191651 | 53.5570256 | CS |
12 | 0.59 | 1.14385420706 | 51.58 | 58.26 | 45.24 | 278431 | 51.13413368 | CS |
26 | 12.87 | 32.7480916031 | 39.3 | 58.26 | 37.55 | 305492 | 48.14058829 | CS |
52 | -7.1 | -11.979078792 | 59.27 | 64.98 | 37.55 | 357593 | 49.14812194 | CS |
156 | 39.8 | 321.746160065 | 12.37 | 64.98 | 4.25 | 344484 | 43.00417947 | CS |
260 | 39.8 | 321.746160065 | 12.37 | 64.98 | 4.25 | 344484 | 43.00417947 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales